Compare RYTM & CAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | CAG |
|---|---|---|
| Founded | 2008 | 1919 |
| Country | United States | United States |
| Employees | N/A | 26100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.9B |
| IPO Year | 2017 | 1994 |
| Metric | RYTM | CAG |
|---|---|---|
| Price | $102.60 | $14.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | ★ $131.14 | $16.88 |
| AVG Volume (30 Days) | 646.7K | ★ 14.6M |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 9.84% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,500,000,000.00 |
| Revenue This Year | $55.34 | N/A |
| Revenue Next Year | $86.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.50 | $12.53 |
| 52 Week High | $122.20 | $20.32 |
| Indicator | RYTM | CAG |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 58.71 |
| Support Level | $98.30 | $13.66 |
| Resistance Level | $113.51 | $16.07 |
| Average True Range (ATR) | 3.76 | 0.54 |
| MACD | -1.65 | 0.06 |
| Stochastic Oscillator | 11.09 | 71.39 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.